View Older Stories View More Recent Stories
-
Jaguar Health (JAGX) CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing
-
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
-
Jaguar Health (JAGX) Announces 1:25 Reverse Share Split
-
Jaguar Health, Inc. Announces Reverse Stock Split
-
Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders
-
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
-
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
-
Jaguar Health (JAGX) Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
-
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
-
Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
-
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
-
Jaguar Health (JAGX) Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
-
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
-
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
-
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (
-
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase
-
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
-
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
-
Jaguar Health (JAGX): Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
-
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
-
Jaguar Health (JAGX) Announces FDA Approval of Orphan-Drug Designation for Crofelemer for Treatment of Diarrhea in Cholera
-
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera
-
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer
-
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
-
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Sy
-
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
-
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine
-
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for T
-
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference
-
Jaguar Health (JAGX) Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
-
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
-
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
-
Jaguar Health (JAGX) Misses Q3 EPS by 105c
-
Jaguar Health Reports Third Quarter 2024 Financial Results
-
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
-
Jaguar Health (JAGX) Announces FDA Approval of Renewal of Canalevia-CA1
-
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
-
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
-
Jaguar Health (JAGX) Presents Significant Positive Results with Crofelemer for Chronic Refractory Diarrhea in IBS-D
-
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
-
Jaguar Health (JAGX) Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
-
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
-
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
-
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
-
Jaguar Health (JAGX) Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
-
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
-
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advo
-
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
